YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth

Imagine your body is a bustling city, and inside that city, every cell is a hardworking citizen with a strict set of rules to follow. Usually, there are special "traffic cops" inside these cells that make sure everything runs smoothly, stopping the citizens from growing too fast or building too many new houses. One of these famous traffic cops is called NF2. Think of NF2 as the city's chief safety officer; its main job is to keep cell growth in check. But sometimes, the blueprints for this officer get damaged or lost (a mutation), and the safety officer disappears. Without NF2, the city's construction crews go wild, building tumors instead of orderly neighborhoods. This is what happens in a type of brain tumor called a meningioma.

When the NF2 officer is missing, another system takes over the controls. It's like a super-charged construction manager named YAP-TEAD who starts shouting orders to build, build, build! Scientists have known for a while that this YAP-TEAD manager is the reason these tumors keep growing, but they didn't know exactly which workers YAP-TEAD was hiring to do the heavy lifting. Finding out who these workers are is crucial because if we can identify them, we might be able to fire them or stop them from working, which could stop the tumor from growing. This is the big question the researchers set out to answer: Who are the specific workers that the YAP-TEAD manager relies on when NF2 is gone?

In this study, the researchers played detective to find the missing link in the NF2-deficient meningioma mystery. They started by looking at the "to-do lists" (transcriptomic profiles) of these tumors and found a worker named CPA4 (carboxypeptidase A4) that was always showing up on the list, working overtime. It turned out that CPA4 wasn't just a random employee; it was a direct order from the YAP-TEAD manager. The team discovered that in real patients, tumors with missing NF2 (or damaged chromosome 22q) were the ones with the highest levels of CPA4. Interestingly, these CPA4-heavy tumors were also the ones that seemed more aggressive and were linked to other genetic changes, like losing chromosome 1p.

To prove that CPA4 was the real deal and not just a bystander, the scientists ran some experiments where they removed CPA4 from the tumor cells. The result was a total shutdown of the tumor's construction site. Without CPA4, the cells couldn't divide properly, their DNA replication and repair systems broke down, and the tumors stopped growing. In fact, when they tested this on models inside the brain, removing CPA4 actually helped the subjects live longer. The researchers also showed that CPA4 is a direct target of the YAP-TEAD signaling, meaning the manager specifically orders its production.

The most exciting part of the story is that this discovery might offer a new way to treat these stubborn tumors. The study suggests that tumors with high levels of CPA4 are especially sensitive to blocking the YAP-TEAD manager. When the researchers used drugs designed to stop YAP-TEAD—specifically a compound called verteporfin and a clinical-stage drug named VT3989—they saw that CPA4 levels dropped, the tumors stopped growing, and survival times improved in the models. While these results are promising, the paper presents them as findings from specific models and assays, suggesting that CPA4 could be a useful biomarker to identify which patients might respond best to these YAP-TEAD inhibitors. Ultimately, this work uncovers a specific dependency in NF2-deficient meningiomas, pointing to a potential new strategy for therapy by targeting the CPA4 worker that the YAP-TEAD manager relies on.